
Abigail L Savage

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3464183/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Innovative approaches for treatment of osteosarcoma. Experimental Biology and Medicine, 2022, 247, 310-316.	1.1	18
2	Characterisation of the Function of a SINE-VNTR-Alu Retrotransposon to Modulate Isoform Expression at the MAPT Locus. Frontiers in Molecular Neuroscience, 2022, 15, 815695.	1.4	7
3	Locus specific reduction of L1 expression in the cortices of individuals with amyotrophic lateral sclerosis. Molecular Brain, 2022, 15, 25.	1.3	2
4	Longitudinal intronic RNA-Seq analysis of Parkinson's disease patients reveals disease-specific nascent transcription. Experimental Biology and Medicine, 2022, 247, 945-957.	1.1	5
5	Mechanisms of disease-associated SINE-VNTR-Alus. Experimental Biology and Medicine, 2022, 247, 756-764.	1.1	7
6	At the dawn of the transcriptomic medicine. Experimental Biology and Medicine, 2021, 246, 286-292.	1.1	7
7	Transcript Variants of Genes Involved in Neurodegeneration Are Differentially Regulated by the APOE and MAPT Haplotypes. Genes, 2021, 12, 423.	1.0	7
8	The TOMM40 â€~523' polymorphism in disease risk and age of symptom onset in two independent cohorts of Parkinson's disease. Scientific Reports, 2021, 11, 6363.	1.6	6
9	Variable number tandem repeats – Their emerging role in sickness and health. Experimental Biology and Medicine, 2021, 246, 1368-1376.	1.1	11
10	Reference SVA insertion polymorphisms are associated with Parkinson's Disease progression and differential gene expression. Npj Parkinson's Disease, 2021, 7, 44.	2.5	22
11	Expression Quantitative Trait Loci (eQTLs) Associated with Retrotransposons Demonstrate their Modulatory Effect on the Transcriptome. International Journal of Molecular Sciences, 2021, 22, 6319.	1.8	10
12	TOMM40 â€~523' poly-T repeat length is a determinant of longitudinal cognitive decline in Parkinson's disease. Npj Parkinson's Disease, 2021, 7, 56.	2.5	2
13	An Increased Burden of Highly Active Retrotransposition Competent L1s Is Associated with Parkinson's Disease Risk and Progression in the PPMI Cohort. International Journal of Molecular Sciences, 2020, 21, 6562.	1.8	18
14	Frequency and methylation status of selected retrotransposition competent L1 loci in amyotrophic lateral sclerosis. Molecular Brain, 2020, 13, 154.	1.3	7
15	Disease-modifying effects of an <i>SCAF4</i> structural variant in a predominantly <i>SOD1</i> ALS cohort. Neurology: Genetics, 2020, 6, e470.	0.9	9
16	Single Nucleotide Polymorphisms Associated With Gut Homeostasis Influence Risk and Age-at-Onset of Parkinson's Disease. Frontiers in Aging Neuroscience, 2020, 12, 603849.	1.7	16
17	Non-coding genetic variation shaping mental health. Current Opinion in Psychology, 2019, 27, 18-24.	2.5	14
18	The Role of SINE-VNTR-Alu (SVA) Retrotransposons in Shaping the Human Genome. International Journal of Molecular Sciences, 2019, 20, 5977.	1.8	22

ABIGAIL L SAVAGE

#	Article	IF	CITATIONS
19	Retrotransposons in the development and progression of amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 284-293.	0.9	29
20	The RNA processing factors THRAP3 and BCLAF1 promote the DNA damage response through selective mRNA splicing and nuclear export. Nucleic Acids Research, 2017, 45, 12816-12833.	6.5	79
21	Molecular signatures of mood stabilisers highlight the role of the transcription factor REST/NRSF. Journal of Affective Disorders, 2015, 172, 63-73.	2.0	10
22	An Evaluation of a SVA Retrotransposon in the FUS Promoter as a Transcriptional Regulator and Its Association to ALS. PLoS ONE, 2014, 9, e90833.	1.1	32
23	Characterisation of the potential function of SVA retrotransposons to modulate gene expression patterns. BMC Evolutionary Biology, 2013, 13, 101.	3.2	55
24	Polymorphic variation as a driver of differential neuropeptide gene expression. Neuropeptides, 2013, 47, 395-400.	0.9	8